Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 5,454 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Solid Neoplasm Clear all
Completed Phase 1 Interventional

SU5416 and Paclitaxel in Treating Patients With Advanced Cancer

NCT00006257
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel, semaxanib
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 22, 2026, 5:18 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

NCT05948865
View directory record Official record
Conditions
Cancer, Cancer, Lung
Interventions
CPO301
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Newport Beach, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 22, 2026, 5:18 AM EDT
Completed Phase 1 Interventional Results available

A Study Of PF-04449913 Administered Alone In Select Solid Tumors

NCT01286467
View directory record Official record
Conditions
Solid Tumors
Interventions
PF-04449913
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 22, 2026, 5:18 AM EDT
Terminated Phase 1 Interventional

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

NCT02556463
View directory record Official record
Conditions
Solid Tumors, CTCL, Cancer
Interventions
MEDI9197, durvalumab
Drug · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 22, 2026, 5:18 AM EDT
Completed Phase 1 Interventional Results available

Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

NCT00069277
View directory record Official record
Conditions
Cancer
Interventions
E7389
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Los Angeles, California • Santa Monica, California • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 22, 2026, 5:18 AM EDT
Completed Phase 1 Interventional Results available

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

NCT01014936
View directory record Official record
Conditions
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Interventions
MSC2156119J
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 22, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

NCT01543763
View directory record Official record
Conditions
Metastatic Solid Tumors
Interventions
PZP115891, PCI-24781
Drug
Lead sponsor
Pamela Munster
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 22, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

NCT02324257
View directory record Official record
Conditions
Solid Tumors
Interventions
RO6958688, Obinutuzumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 22, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors

NCT01357330
View directory record Official record
Conditions
Solid Tumors
Interventions
SAR245408 (XL147), MSC1936369B
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 22, 2026, 5:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

NCT07189871
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), Sarcoma
Interventions
177Lu-BetaBart, BetaBart + unlabeled BetaBart
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 5:18 AM EDT
Terminated Phase 1 Interventional

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

NCT05233436
View directory record Official record
Conditions
Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinomas
Interventions
PF-07265028, Sasanlimab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • Iowa City, Iowa • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 22, 2026, 5:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709
View directory record Official record
Conditions
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Interventions
BMS-986340, BMS-936558-01, Docetaxel, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
Clovis, California • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 5:18 AM EDT
Terminated Phase 1 Interventional

A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

NCT05387265
View directory record Official record
Conditions
Solid Tumors
Interventions
CX-904
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Denver, Colorado • Nashville, Tennessee • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 22, 2026, 5:18 AM EDT
Recruiting Phase 1 Interventional

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

NCT06598800
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Drug: BG-T187, Other Therapeutic Agents
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Hackensack, New Jersey • Houston, Texas • Fairfax, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional Results available

OLAParib COmbinations

NCT02576444
View directory record Official record
Conditions
Cancer
Interventions
AZD2281, AZD5363, AZD1775, AZD6738
Drug
Lead sponsor
Joseph Paul Eder
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 22, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas

NCT01051635
View directory record Official record
Conditions
Neoplasms, Lymphoma
Interventions
LMP400, LMP776
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 22, 2026, 5:18 AM EDT
Completed No phase listed Observational

Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry

NCT02852252
View directory record Official record
Conditions
Bladder Cancer, Gastric Cancer
Interventions
OTL38, ICG
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 22, 2026, 5:18 AM EDT
Terminated Phase 1 Interventional

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

NCT00089089
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
decitabine, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 22, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 5:18 AM EDT
Withdrawn Early Phase 1 Interventional

Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients

NCT06922825
View directory record Official record
Conditions
Solid Tumor Cancer, Solid Tumor Malignancy, Cancer, Malignancy
Interventions
68Ga-FAPI-46
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 22, 2026, 5:18 AM EDT
Not listed Phase 1 Interventional

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00324597
View directory record Official record
Conditions
Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
gemcitabine hydrochloride, motesanib diphosphate, pharmacological study
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 22, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma

NCT00486135
View directory record Official record
Conditions
Cancer, Lymphoma
Interventions
XL147 (SAR245408)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Augusta, Georgia • Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 22, 2026, 5:18 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

NCT06884618
View directory record Official record
Conditions
Neoplasms
Interventions
RO7673396
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Duarte, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors

NCT02004106
View directory record Official record
Conditions
Neoplasms
Interventions
RO6895882
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 22, 2026, 5:18 AM EDT